Cynata Therapeutics Ord Shs V.CYP

Primary Symbol: CYYNF

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

OTCPK:CYYNF - Post by User

Cynata Therapeutics Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by fulogas1on Jan 26, 2021 8:41am

238 Views

Post# 32385525

Going forward ....Step by step

https://www.globenewswire.com/news-release/2020/11/27/2135298/0/en/Cypress-Development-Announces-Extension-to-Nevada-Option-Agreement-with-Pasinex.html

After looking at the losses that Pasinex is incurring .. I wonder if they will be able to complete their earn-in ??

I wonder if Is there any possibility that we may end with it all back in full control of Cypress. ??

<< Previous

Bullboard Posts

Next >>

Unsung profits: Three money-making penny stocks trading for cheap